The latest update is out from Virax Biolabs Group Ltd. Class A ( (VRAX) ).
On February 25, 2025, Virax Biolabs Group Limited announced that its technology aligns with the United States Department of Health and Human Services’ commitment to enhancing transparency in vaccine efficacy. This alignment positions Virax Biolabs to support public health by providing data-driven insights into vaccine efficacy and immune profiles, empowering informed vaccination decisions. The company’s innovative platform is designed to advance research in protective immunity and T cell dysfunction, furthering its role in vaccine development and public health initiatives.
More about Virax Biolabs Group Ltd. Class A
Virax Biolabs Group Limited is an innovative biotechnology company focused on detecting immune responses and diagnosing viral diseases. The company is currently developing T-Cell-based test technologies aimed at providing an immunology profiling platform, which can be particularly effective in diagnosing and treating post-viral syndromes such as Long COVID and other chronic conditions linked to immune dysregulation.
YTD Price Performance: -21.72%
Average Trading Volume: 390,273
Technical Sentiment Consensus Rating: Buy
See more insights into VRAX stock on TipRanks’ Stock Analysis page.